Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseum.
Ann Soc Belg Med Trop
; 75(3): 211-7, 1995 Sep.
Article
em En
| MEDLINE
| ID: mdl-8849298
ABSTRACT
A Columbian patient presented with a rare type of onychomycosis caused by Microsporum gypseum. Oral treatment with itraconazole formulation (Funazol) available in Columbia failed to improve the nail alteration. The fungitoxic effect of itraconazole was assessed on the M. gypseum strain cultured from the nail of the patient by using the method of culture of fungi on cyanoacrylate skin surface strippings (CSSS). In addition, a comparative evaluation of the oral bioavailability of itraconazole was made in volunteers after intake of Funazol and Sporanox. In the ex vivo bioassay on CSSS, topical itraconazole proved to be highly active against M. gypseum. After oral intake, however, the itraconazole bioavailability of Funazol relative to Sporanox averaged only 3.5%. Antifungal pulse therapy with Sporanox, 400 mg daily for 1 week per month for 4 months, cured the patient. This study shows that itraconazole is hardly or not absorbed from the oral formulation Funazol. Both the oral bioavailability and consequently therapeutic efficacy of the genuine drug (Sporanox) are highly superior.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Onicomicose
/
Itraconazol
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Ann Soc Belg Med Trop
Ano de publicação:
1995
Tipo de documento:
Article
País de afiliação:
Bélgica